Palisade bio regains compliance with nasdaq listing requirements

Carlsbad, ca, dec. 01, 2022 (globe newswire) -- palisade bio, inc. (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, today announced that on december 1, 2022, it received notice from the nasdaq stock market llc (nasdaq) that it has regained compliance with the nasdaq listing rules for continued listing on the nasdaq capital market.
PALI Ratings Summary
PALI Quant Ranking